Mesenchymal stromal/stem cell (MSC)-derived exosomes in clinical trials

Area of Science:

• Cellular and Molecular Medicine
• Regenerative Medicine
• Immunotherapy

Background:

• Mesenchymal stromal/stem cells (MSCs) are valued for immunomodulatory and regenerative properties, primarily through paracrine activity.
• Extracellular vesicles, particularly exosomes, secreted by MSCs (MSC-Exos) are key mediators of therapeutic efficacy.
• MSC-Exos present advantages over MSCs, including reduced infusion-related toxicities, positioning them as a promising cell-free therapeutic tool.

Purpose of the Study:

• To review ongoing and completed clinical studies investigating MSC-Exos for various therapeutic applications.
• To summarize production methods, including MSC source, isolation, characterization, dosage, and administration routes for MSC-Exos.
• To discuss current challenges and future directions for exosome-based therapeutic strategies.

Main Methods:

• Systematic review of clinical studies involving MSC-Exos.
• Analysis of MSC-Exos production and characterization methodologies.
• Evaluation of therapeutic outcomes in immunomodulation, regenerative medicine, and gene delivery applications.

Main Results:

• Clinical studies are assessing MSC-Exos for immunomodulation, regenerative medicine, and gene delivery.
• Varied MSC sources, isolation techniques, characterization methods, dosages, and administration routes are employed.
• MSC-Exos demonstrate potential as a cell-free therapeutic alternative with reduced adverse effects.

Conclusions:

• MSC-Exos are emerging as a potent cell-free therapeutic strategy with broad clinical applications.
• Standardization of MSC-Exos production and characterization is crucial for clinical translation.
• Further research is needed to overcome challenges and optimize exosome utilization in novel therapeutic strategies.